Browsing: ESMO
ESMO 2022: Highlights on neo-adjadjuvant vs adjuvant pembrolizumab in resected stage III-IV melanoma: SWOG S1801
ESMO 2022: Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 study
ESMO 2022: Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD
ESMO 2022: Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study
ESMO 2022: Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma
“It’s not just what you give, it’s when you give it! SWOG S1801 demonstrates that…
ESMO 2022: Strong potential for neoadjuvant nivolumab plus ipilimumab to become standard of care for locally advanced MMR-deficient colon cancer
“In the NICHE-2 study, two cycles of neoadjuvant nivolumab plus low-dose ipilimumab led to unprecedented…
Pembrolizumab with CRT vs placebo plus CRT for locally advanced HNSCC
Study lead Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc (UCLouvain) and Institut de Recherche Clinique et Expérimentale (Pole…
ESMO 2022: ADAURA trial results provide new hope for patients with early-stage non-small cell lung cancer
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
ESMO 2022: Cabozantinib plus nivolumab and ipilimumab shows significant PFS benefit for aRCC patients of intermediate or poor risk
“COSMIC-313 is the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet…